Duloxetine (LY 248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate

Bibliography

• WONG DT, BYMASTER FP, MOYLE DA et al: LY248686, a new inhibitor of serotonin and noradrenaline uptake. Neuropsychopharmacology (1993) 8:23–33.
   PubMed Web of Science ®Google Scholar
• RICHELSON E: Pharmacology of antidepressants. Psy-chopathology (1987) 20 (Suppl. 0:1–12
   Google Scholar
• WONG DT, BYMASTER FP: The comparison of fluoxet-ine and nisoxetine with tricyclic antidepressants in blocking the neurotoxicity of p-chloroamphetamine and 6-hydroxydopamine in the rat brain. Res. Comm. Chem. Pathol. Pharmacol (1976) 15:221–231.
   PubMedGoogle Scholar
• KASAMO K, BLIER P, DE MONTIGNY C: Blockade of the serotonin and noradrenaline uptake processes by du-loxetine: in vitro and in vivo studies in the rat brain. J. Pharmacol. Exp. Ther. (1966) 277:278–286.
   Google Scholar
• KASAHARA T, ISHIGOOKA J, NAGATA E, MURASAKI M, MIURA S: Long-lasting inhibition of 5-HT uptake of platelets in subjects treated by duloxetine, a potential antidepressant. Jpn. J. Psychopharmacol (1996) 16:25–31.
   Google Scholar
• TATSUMI M, GROSHAN K, BLAKELY RD, RICHELSON E: Pharmacological profile of antidepressant and related compounds at human monoamine transporters. Eur. J. Pharmacol. (1997) 340:249–258.
   PubMed Web of Science ®Google Scholar
• MUTH EA, HASKINS JT, MOYER JA et al.: Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem. Pharmacol (1986) 35:4493–4497.
   PubMed Web of Science ®Google Scholar
• MORET C, CHARVERON M, FINBERG JPM, COUZINIER JP, BRILEY M: Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbony1-2-aminomethyl-cy clopropane (Z) hydrochloride, a potential fourth gen-eration antidepressant drug. Neuropharmacology (1985) 24:1211–1219.
   PubMed Web of Science ®Google Scholar
• ENGLEMAN EA, PERRY KW, LE DA, WONG DT: Simulta-neous increases of extracellular monoamines in mi-crodialysis from hypothalamus of conscious rats by duloxetine, a dual serotonin and noradrenaline up-take inhibitor. Neuropsychopharmacology (1995) 12:287–295.
   PubMedGoogle Scholar
• WONG DT, THRELKELD PG, BEST KL, BYMASTER FP: Anew inhibitor of noradrenaline uptake devoid of affin-ity for receptors of rat brain. J. Pharmacol. Exp. Ther. (1982) 222:61–65.
   PubMed Web of Science ®Google Scholar
• FULLER RW, HEMRICK-LUECKE SK, SNODDY HD: Effectsof duloxetine, an antidepressant drug candidate, on concentrations of monoamines and their metabolites in rats and mice. J. Pharmacol Exp. Ther. (1994) 269:132–136.
   PubMed Web of Science ®Google Scholar
• FULLER RW, SNODDY HD, PERRY KW, BYMASTER FP,WONG DT: Importance of duration of drug action in the antagonism of p-chloroamphetamine depletion of brain serotonin-comparison of fluoxetine and chlo-rimipramine. Biochem. Pharmacol. (1978) 27:193–198.
   PubMed Web of Science ®Google Scholar
• CHAPUT Y, DE MONTIGNY C, BLIER P: Effects of a selec-tive 5-HT re-uptake blocker, citalopram, on the sensi-tivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn-Schiedberg's Arch. Phar-macol. (1986) 333:342–348.
   PubMed Web of Science ®Google Scholar
• GARTSIDE SE, UMBERS V, SHARP T: Inhibition of 5-HTcell firing in the DRN by non-selective 5-HT re-uptake inhibitors: studies on the role of 5-HT1A autoreceptors and noradrenergic mechanisms. Psychopharmacology (1997) 130:261–268.
   PubMed Web of Science ®Google Scholar
• SALTER M, HAZELWOOD R, POGSON CI et al.: The effectsof an inhibitor of tryptophan 2,3-dioxygenase and a combined inhibitor of tryptophan 2,3-dioxygenase and 5-HT re-uptake in the rat. Neuropharmacology (1995) 34:217–227.
   PubMed Web of Science ®Google Scholar
• SCUVEE-MOREAU JJ, DRESSE AE: Effect of various anti-depressant drugs on the spontaneous firing rate of lo-cus coeruleus and dorsal raphe neurons of the rat. Eur. Pharmacol. (1979) 57:219–225.
   PubMed Web of Science ®Google Scholar
• KIHARA T, IKEDA M: Effects of duloxetine, a new sero-tonin and noradrenaline uptake inhibitor, on extra-cellular monoamine levels in rat frontal cortex. J. Pharmacol. Exp. Ther. (1995) 272:177–183.
   PubMed Web of Science ®Google Scholar
• HJORTH S: Serotonin 5-HTIA autoreceptor blockade potentiates the ability of the 5-HT re-uptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo, a microdialysis study. J. Neurochem. (1993) 60:776–779.
   PubMed Web of Science ®Google Scholar
• WONG DT, BYMASTER FP, ENGLEMAN EA: Presynapticregulation of extracellular serotonin concentrations in brain. In: Serotonin in the Central Nervous System and Periphery, (Ed.), Takada A, Curzon G. Int. Cong Series 1088, Excerpta Medica, Elsevier, Amsterdam (1995):3–13.
   Google Scholar
• ENGLEMAN EA, ROBERTSON DW, THOMPSON DC, PERRY KW, WONG DT: Antagonism of serotonin 5-HT1A receptors potentiates the increases in extracellular monoamines induced by duloxetine in rat hypothala-mus. J. Neurochem. (1996) 66:599–603.
   PubMed Web of Science ®Google Scholar
• MILLAN MJ, BROCCO M, VEIGA S et al: WAY 100635 en-hances both the antidepressant actions of duloxetine and its influence on dialysate levels of serotonin in frontal cortex. Eur. J. Pharmacol (1998) 341:165–167.
   PubMed Web of Science ®Google Scholar
• GOBERT A, RIVET J-M, CISTARELLI L, MELON C, MILLANMJ: Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced in-creases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats. J. Neu-rochem. (1997) 69:2616–2619.
   PubMed Web of Science ®Google Scholar
• TRENDELBERG AU, STARKE K, LIMBERGER N: Presynap-tic alpha-2-adrenoceptors inhibit the release of endogenous dopamine in rabbit caudate nucleus slices. Naunyn-Schiedberg's Arch.Pharmacol (1994) 84:413–429.
   Google Scholar
• GOBERT A, AUDINOT RV, NEWMAN-TANCREDI A et al.: Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex di-alysates of freely-moving rats reveals a complex pat-tern reciprocal auto- and heteroreceptor-mediated control of release. Neuroscience (1998) 84:413–419.
   PubMed Web of Science ®Google Scholar
• KATOH A, EIGYO M, ISHIBASHI C et al.: Behavioural and electroencephalographic properties of duloxetine (LY248686), a re-uptake inhibitor of noradrenaline and serotonin, in mice and rats. J. Pharmacol Exp. Ther. (1995) 272:1067–1075.
   PubMed Web of Science ®Google Scholar
• RENERIC J-P, LUCKI I: Antidepressant behavioural ef-fects by dual inhibition of monoamine re-uptake in the rat forced swimming test. Psychopharmacology (1998) 136:190–197.
   PubMed Web of Science ®Google Scholar
• BERK M, DU PLESSIS A, BIRKETT M, RICHARDT D ON BE-HALF OF THE LILLY DULOXETINE DEPRESSION STUDY GROUP: An open-label study of duloxetine hydrochlo-ride, a mixed serotonin and noradrenergic re-uptake inhibitor, in patients with DSM-III-R major depressive disorder. Int. Clin. Psychopharmacol. (1997) 12:137–140.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI A, WAKATABE H, MURASAKI M: Pharma-cokinetics after single administration of LY248686 (duloxetine) in normal subjects. Am. Coll. Neuropsycho-pharmacol (1997):152. Abstract
   Google Scholar
• TAKAHASHI A, WAKATABE H, KUMAGAI Y, YOKOTA S-I, MURASAKI M: Safety and pharmacokinetics after 7-day repeated administration of 20 mg and 40 mg of LY248686 (duloxetine) in healthy subjects. Am. Coll. Neuropsycho-pharmacol (1997):263. Abstract
   Google Scholar
• MURASAKI M: Clinical optimum dose of LY248686 (du-loxetine) for treatment of depression and depressive state (a double-blind inter-group comparison study us-ing imipramine hydrochloride as a comparator prod-uct). Am. Coll. Neuropsychopharmacol (1997)264. Abstr.
   Google Scholar
• DELGADO PL, CHARNEY DS, PRICE LH et al: Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch. Gen. Psychiatry (1990) 47:411–418.
   PubMed Web of Science ®Google Scholar
• MILLER HL, DELGADO PL, SALOMON R et al.: Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch. Gen. Psychiatry (1996) 53:117–128.
   PubMed Web of Science ®Google Scholar
• NELSON JC: Augmentation strategy with serotonergic-noradrenergic combinations. J. Clin. Psychiatry (1998) 59 (Suppl. 5):65–69.
   Google Scholar